Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Yahoo! Finance
This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 47.76%. A quarter ago, it was expected that this company would post earnings of $0.65 per share when it actually produced earnings of $1.55, delivering a surprise of 138.46%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Entrada Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $19.57 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 20.43%. This compares to year-ago revenues of $43.74 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings cal
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.MarketBeat
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyGlobeNewswire
TRDA
Earnings
- 11/5/24 - Beat
TRDA
Sec Filings
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- 11/6/24 - Form 4
- TRDA's page on the SEC website